141 related articles for article (PubMed ID: 8991644)
1. Antibody response to human parvovirus B19 in patients with primary infection by immunoblot assay with recombinant proteins.
Palmer P; Pallier C; Leruez-Ville M; Deplanche M; Morinet F
Clin Diagn Lab Immunol; 1996 Mar; 3(2):236-8. PubMed ID: 8991644
[TBL] [Abstract][Full Text] [Related]
2. Anti-VP1 and anti-VP2 antibodies detected by immunofluorescence assays in patients with acute human parvovirus B19 infection.
Pereira RF; Paula WN; Cubel Rde C; Nascimento JP
Mem Inst Oswaldo Cruz; 2001 May; 96(4):507-13. PubMed ID: 11391423
[TBL] [Abstract][Full Text] [Related]
3. [Responsiveness of a new parvovirus B19 antigen produced in baculovirus expression system to B19-specific IgG and IgM antibodies in every epidemic, 1968, 1980, 1987 and 1992 in Japan].
Nunoue T
Kansenshogaku Zasshi; 1995 May; 69(5):546-52. PubMed ID: 7602188
[TBL] [Abstract][Full Text] [Related]
4. A recombinant immunoblot and ELISA for detection of acute parvovirus B19 infection.
Schwarz TF; Jäger G
Zentralbl Bakteriol; 1994 Mar; 280(4):526-33. PubMed ID: 8061414
[TBL] [Abstract][Full Text] [Related]
5. Impaired gamma interferon responses against parvovirus B19 by recently infected children.
Corcoran A; Doyle S; Waldron D; Nicholson A; Mahon BP
J Virol; 2000 Nov; 74(21):9903-10. PubMed ID: 11024117
[TBL] [Abstract][Full Text] [Related]
6. Antibody response to B19 parvovirus VP1 and VP2 linear epitopes in patients with haemophilic arthritis.
Azzi A; Manaresi E; Zakrzewska K; DeSantis R; Musiani M; Zerbini M
J Med Virol; 2004 Apr; 72(4):679-82. PubMed ID: 14981773
[TBL] [Abstract][Full Text] [Related]
7. Detection of human parvovirus B19-specific IgM and IgG antibodies using a recombinant viral VP1 antigen expressed in insect cells and estimation of time of infection by testing for antibody avidity.
Gray JJ; Cohen BJ; Desselberger U
J Virol Methods; 1993 Sep; 44(1):11-23. PubMed ID: 8227275
[TBL] [Abstract][Full Text] [Related]
8. Differential IgM response to conformational and linear epitopes of parvovirus B19 VP1 and VP2 structural proteins.
Manaresi E; Zuffi E; Gallinella G; Gentilomi G; Zerbini M; Musiani M
J Med Virol; 2001 May; 64(1):67-73. PubMed ID: 11285571
[TBL] [Abstract][Full Text] [Related]
9. Recombinant parvovirus B19 capsids as a new substrate for detection of B19-specific IgG and IgM antibodies by an enzyme-linked immunosorbent assay.
Salimans MM; van Bussel MJ; Brown CS; Spaan WJ
J Virol Methods; 1992 Sep; 39(3):247-58. PubMed ID: 1430069
[TBL] [Abstract][Full Text] [Related]
10. A synthetic parvovirus B19 capsid protein can replace viral antigen in antibody-capture enzyme immunoassays.
Kock WC
J Virol Methods; 1995 Sep; 55(1):67-82. PubMed ID: 8576310
[TBL] [Abstract][Full Text] [Related]
11. Undenatured parvovirus B19 antigens are essential for the accurate detection of parvovirus B19 IgG.
Kerr S; O'Keeffe G; Kilty C; Doyle S
J Med Virol; 1999 Feb; 57(2):179-85. PubMed ID: 9892405
[TBL] [Abstract][Full Text] [Related]
12. Quantitative analysis of neutralizing immune responses to human parvovirus B19 using a novel reverse transcriptase-polymerase chain reaction-based assay.
Bostic JR; Brown KE; Young NS; Koenig S
J Infect Dis; 1999 Mar; 179(3):619-26. PubMed ID: 9952368
[TBL] [Abstract][Full Text] [Related]
13. Prokaryotic expression of a VP1 polypeptide antigen for diagnosis by a human parvovirus B19 antibody enzyme immunoassay.
Söderlund M; Brown KE; Meurman O; Hedman K
J Clin Microbiol; 1992 Feb; 30(2):305-11. PubMed ID: 1537897
[TBL] [Abstract][Full Text] [Related]
14. Use of recombinant human parvovirus B19 antigens in serological assays.
Cubie HA; Leslie EE; Smith S; O'Neill HJ; Hart H; Cohen BJ; Inglis JM
J Clin Pathol; 1993 Sep; 46(9):840-5. PubMed ID: 8227436
[TBL] [Abstract][Full Text] [Related]
15. Antibody-mediated opsonization of red blood cells in parvovirus B19 infection.
Chehadeh W; Halim MA; Al-Nakib W
Virology; 2009 Jul; 390(1):56-63. PubMed ID: 19450862
[TBL] [Abstract][Full Text] [Related]
16. Follow-up study of clinical and immunological findings in patients presenting with acute parvovirus B19 infection.
Kerr JR; Coyle PV; DeLeys RJ; Patterson CC
J Med Virol; 1996 Jan; 48(1):68-75. PubMed ID: 8825713
[TBL] [Abstract][Full Text] [Related]
17. IgG immune response to B19 parvovirus VP1 and VP2 linear epitopes by immunoblot assay.
Manaresi E; Gallinella G; Zerbini M; Venturoli S; Gentilomi G; Musiani M
J Med Virol; 1999 Feb; 57(2):174-8. PubMed ID: 9892404
[TBL] [Abstract][Full Text] [Related]
18. Antibody responses in parvovirus B19 infected patients.
Modrow S; Dorsch S
Pathol Biol (Paris); 2002 Jun; 50(5):326-31. PubMed ID: 12116851
[TBL] [Abstract][Full Text] [Related]
19. Chronic human parvovirus B19 infection in rheumatic disease of childhood and adolescence.
Lehmann HW; Kühner L; Beckenlehner K; Müller-Godeffroy E; Heide KG; Küster RM; Modrow S
J Clin Virol; 2002 Aug; 25(2):135-43. PubMed ID: 12367647
[TBL] [Abstract][Full Text] [Related]
20. Parvovirus infection in children with AIDS: high prevalence of B19-specific immunoglobulin M and G antibodies.
Nigro G; Luzi G; Fridell E; Ferrara M; Pisano P; Gattinara GC; Mezzaroma I; Söderlund M; Rasnoveanu D; Aiuti F
AIDS; 1992 Jul; 6(7):679-84. PubMed ID: 1503687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]